CA2518193A1 - Utilisation d'agonistes selectifs du recepteur ep2 dans un traitement medical - Google Patents

Utilisation d'agonistes selectifs du recepteur ep2 dans un traitement medical Download PDF

Info

Publication number
CA2518193A1
CA2518193A1 CA002518193A CA2518193A CA2518193A1 CA 2518193 A1 CA2518193 A1 CA 2518193A1 CA 002518193 A CA002518193 A CA 002518193A CA 2518193 A CA2518193 A CA 2518193A CA 2518193 A1 CA2518193 A1 CA 2518193A1
Authority
CA
Canada
Prior art keywords
alkylene
alkyl
independently
facilitating
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002518193A
Other languages
English (en)
Inventor
Alexander Angelo Constan
Prakash Raj Keshary
David Burton Maclean
Vishwas Madhav Paralkar
Doina Cosma Roman
David Duane Thompson
Timothy Michael Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc.
Alexander Angelo Constan
Prakash Raj Keshary
David Burton Maclean
Vishwas Madhav Paralkar
Doina Cosma Roman
David Duane Thompson
Timothy Michael Wright
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc., Alexander Angelo Constan, Prakash Raj Keshary, David Burton Maclean, Vishwas Madhav Paralkar, Doina Cosma Roman, David Duane Thompson, Timothy Michael Wright filed Critical Pfizer Products Inc.
Publication of CA2518193A1 publication Critical patent/CA2518193A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002518193A 2003-03-04 2004-02-23 Utilisation d'agonistes selectifs du recepteur ep2 dans un traitement medical Abandoned CA2518193A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45188903P 2003-03-04 2003-03-04
US60/451,889 2003-03-04
PCT/IB2004/000553 WO2004078169A1 (fr) 2003-03-04 2004-02-23 Utilisation d'agonistes selectifs du recepteur ep2 dans un traitement medical

Publications (1)

Publication Number Publication Date
CA2518193A1 true CA2518193A1 (fr) 2004-09-16

Family

ID=32962656

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002518193A Abandoned CA2518193A1 (fr) 2003-03-04 2004-02-23 Utilisation d'agonistes selectifs du recepteur ep2 dans un traitement medical

Country Status (14)

Country Link
EP (1) EP1601351A1 (fr)
JP (1) JP2006519250A (fr)
KR (1) KR20050105511A (fr)
CN (1) CN1859903A (fr)
AU (1) AU2004216898A1 (fr)
BR (1) BRPI0408061A (fr)
CA (1) CA2518193A1 (fr)
CL (1) CL2004000412A1 (fr)
MX (1) MXPA05009398A (fr)
NZ (1) NZ541828A (fr)
PL (1) PL378748A1 (fr)
TW (1) TW200424176A (fr)
WO (1) WO2004078169A1 (fr)
ZA (1) ZA200506532B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
EP1661580B1 (fr) * 2003-07-25 2014-01-08 Ono Pharmaceutical Co., Ltd. Remede destine a traiter des maladies liees au cartilage
ES2644450T3 (es) 2004-12-31 2017-11-29 Dr. Reddy's Laboratories Ltd. Nuevos derivados de bencilamina como inhibidores de CETP
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US7915316B2 (en) 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
WO2007112084A2 (fr) 2006-03-24 2007-10-04 Children's Medical Center Corporation Procédé permettant de moduler la croissance de cellules souches hématopoïétiques
AU2007280130B2 (en) 2006-07-28 2011-09-22 Pfizer Products Inc. EP2 agonists
WO2008070310A2 (fr) * 2006-10-20 2008-06-12 Children's Medical Center Corporation Procédé permettant d'améliorer la régénération tissulaire
EP2195656A4 (fr) * 2007-08-21 2011-10-19 Senomyx Inc Recepteurs humains t2r sensibles aux composes amers qui provoquent le gout amer, et utilisation de ceux-ci
PT2264009T (pt) * 2008-03-12 2019-04-29 Ube Industries Composto do ácido piridilaminoacético
WO2010091052A2 (fr) 2009-02-03 2010-08-12 Children's Medical Center Corporation Procédés de renforcement de greffe de cellule souche hématopoïétique/progénitrice
WO2010096264A2 (fr) 2009-02-03 2010-08-26 Children's Medical Center Corporation Procédés permettant d'améliorer la greffe de cellules souches hématopoïétiques et les cellules progénitrices hématopoïétiques
PL2415763T3 (pl) * 2009-03-30 2016-05-31 Ube Industries Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry
WO2010116270A1 (fr) 2009-04-10 2010-10-14 Pfizer Inc. Agonistes de ep2/4
WO2011030865A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés benzyliques substitués
WO2011030873A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés benzyliques
WO2011030872A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés sulfonamide
WO2011030871A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés hétéroaryle n-substitués
CA2773998A1 (fr) * 2009-09-11 2011-03-17 Ube Industries, Ltd. Composes carbonyle substitues
US20120184747A1 (en) * 2009-09-11 2012-07-19 Ube Industries, Ltd. Aniline compound
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
AU2010336248A1 (en) * 2009-12-25 2012-08-02 Ube Industries, Ltd. Aminopyridine compound
CA2845284C (fr) 2011-08-18 2018-03-06 Dr. Reddy's Laboratories Ltd. Composes amines heterocycliques substitues comme inhibiteurs de la proteine de transfert d'ester cholesterylique (cetp)
JP6140168B2 (ja) 2011-09-27 2017-05-31 ドクター レディズ ラボラトリーズ リミテッド アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての５−ベンジルアミノメチル−６−アミノピラゾロ［３，４−ｂ］ピリジン誘導体
AU2012321088B8 (en) 2011-12-02 2016-12-15 Fate Therapeutics, Inc. Enhanced stem cell composition
ES2682255T3 (es) 2011-12-02 2018-09-19 Fate Therapeutics, Inc. Métodos mejorados de tratamiento de isquemia
EP2804605A4 (fr) * 2012-01-20 2015-07-08 Acucela Inc Composés hétérocycliques substitués pour le traitement d'une maladie
JP2015537028A (ja) * 2012-11-16 2015-12-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 皮膚修復のための組成物および方法
EP2968416A4 (fr) 2013-03-15 2016-08-17 Fate Therapeutics Inc Essai d'activité biologique de cellules pour un potentiel thérapeutique
TW201527282A (zh) 2013-03-28 2015-07-16 Ube Industries 取代聯芳基化合物
WO2015175487A1 (fr) 2014-05-13 2015-11-19 Novartis Ag Composés et compositions d'induction de la chondrogenèse
CN106397149B (zh) * 2016-08-26 2019-05-21 大连奇凯医药科技有限公司 五氟苯甲醛的制备方法
CN115636761A (zh) * 2021-07-20 2023-01-24 中国石油天然气股份有限公司 一种油溶性表面活性剂、驱油剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2113787A1 (fr) * 1993-01-29 1994-07-30 Nobuyuki Hamanaka Sulfonamides carbocycliques
CA2275595C (fr) * 1996-12-20 2003-08-05 Pfizer Inc. Prevention et traitement d'affections osseuses avec des agonistes de la prostaglandine e2 selectifs du sous-type de recepteur ep2
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US6376533B1 (en) * 2000-10-20 2002-04-23 Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists

Also Published As

Publication number Publication date
KR20050105511A (ko) 2005-11-04
JP2006519250A (ja) 2006-08-24
CL2004000412A1 (es) 2005-02-04
WO2004078169A1 (fr) 2004-09-16
TW200424176A (en) 2004-11-16
BRPI0408061A (pt) 2006-02-14
EP1601351A1 (fr) 2005-12-07
ZA200506532B (en) 2007-03-28
PL378748A1 (pl) 2006-05-15
NZ541828A (en) 2008-06-30
CN1859903A (zh) 2006-11-08
AU2004216898A1 (en) 2004-09-16
WO2004078169A8 (fr) 2005-04-21
MXPA05009398A (es) 2005-12-05

Similar Documents

Publication Publication Date Title
CA2518193A1 (fr) Utilisation d'agonistes selectifs du recepteur ep2 dans un traitement medical
CA2305548C (fr) Agonistes de la prostaglandine et leur utilisation pour le traitement des problemes osseux
AU721260B2 (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
US20050203086A1 (en) Methods of treatment using an EP2 selective receptor agonist
MXPA00003478A (en) Prostaglandin agonists and their use to treat bone disorders
CZ20001280A3 (cs) Agonisté prostaglandinu a jejich použití pro léčení chorob kostí

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued